RTI-371 is a highly selective atypical dopamine transporter (DAT) inhibitor that crosses the blood-brain barrier. RTI-371 exhibits potent inhibitory activity in cell lines transfected with human DAT ( IC 50 = 8.7 nM) and shows high binding affinity for rat DAT with a K i value of 7.81 nM. RTI-371 also acts as a positive allosteric modulator of the human cannabinoid 1 receptor (hCB1 receptor), enhancing the activity of cannabinoid receptor agonists in a concentration-dependent manner. RTI-371 can be used for the research of Parkinson's disease.
Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Dopamine Transporter | Products > Signaling Pathways > Serotonin Transporter | Products > Signaling Pathways > Cannabinoid Receptor | Products > Signaling Pathways > Sigma Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.